510(k) · Cleared
ClearedCryocheck Clot S
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Precision Biologic, Inc. · GGP Test, Qualitative And Quantitative Factor Deficiency
Cleared on Mar 18, 2005 as substantially equivalent to K913424 (American Bioproducts Co., 1991) after an 81-day review. Its family tree reaches back 1 generation to 1991.
- Decided
- Mar 18, 2005
- Review
- 81 days
- Class
- Class II
- Product code
- GGP
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K913424 (1991). No later device cites it as a predicate yet.
- Root · 1 generation backK913424 Staclot (R) Protein S Test KitAmerican Bioproducts Co. · 1991 · Recalled
- This deviceK043571 Cryocheck Clot SPrecision Biologic, Inc. · 2005
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K913424 | Staclot (R) Protein S Test Kit | American Bioproducts Co. | 1991 | 1 |
| 0 (this device) | K043571 | Cryocheck Clot S | Precision Biologic, Inc. | 2005 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in GGP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new GGP device
- #1 K251440 CRYOcheck Chromogenic Factor VIIIscore 10.5 · 3 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K913424 | Staclot (R) Protein S Test KitSummary page 1…Test, Qualitative and Quantitative Factor Deficiency Regulatory Class II Predicate Device: STA® - Staclot® Protein S (K913424) Diagnostica Stago 9, rue des Fr~res Chausson… | 1991 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has a recall.
- 2 other devices also cite its predicate K913424.
How does its category compare?
All GGP devicesGGP Test, Qualitative And Quantitative Factor Deficiency: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · GGP
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · GGP
153in 2007
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · GGP
1in 2017
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · GGP
3in 2025
MAUDE reports naming product code GGP, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 3 | 153 | 2 | 0 |
| 2008 | 2 | — | 0 | 0 |
| 2009 | 1 | — | 0 | 0 |
| 2010 | 0 | — | 1 | 0 |
| 2011 | 1 | — | 0 | 0 |
| 2012 | 0 | — | 2 | 4 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 1 |
| 2015 | 0 | — | 2 | 1 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 1 | 3 |
| 2018 | 1 | — | 0 | 3 |
| 2019 | 1 | — | 0 | 1 |
| 2020 | 2 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 2 |
| 2022 | 2 | — | 0 | 4 |
| 2023 | 2 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 1 | — | 0 | 3 |
| 2026 | 0 | — | 1 | — |
What is it indicated for?
CRYocheckA Clot S- is a clot-based assay intended for the quantitative determination of protein S activity in citrated human plasma. c¢RYOcheck- Clot S- is used to diagnose protein S deficiency (congenital or acquired) which is indicative of an increased risk of thromboembolism. A deficiency in protein S may produce recurrent thrombotic episodes. Congenital deficiencies of protein S are classified as three types: * type I deficiencies correspond to…
Read the full statement (165 words)
CRYocheckA Clot S- is a clot-based assay intended for the quantitative determination of protein S activity in citrated human plasma.
c¢RYOcheck- Clot S- is used to diagnose protein S deficiency (congenital or acquired) which is indicative of an increased risk of thromboembolism. A deficiency in protein S may produce recurrent thrombotic episodes.
Congenital deficiencies of protein S are classified as three types:
* type I deficiencies correspond to reduced antigen levels of both total and free protein S
* type II deficiencies are characterized by a reduced protein S activity but with normal antigen levels of both total and free protein S
* type III deficiencies are defined by a reduced antigen level and activity of free protein S but the antigen level of total protein S remains normal
Acquired protein S deficiencies are associated with several clinical states:
- oral anticoagulant therapy
- liver disease
- disseminated intravascular coagulation
* oral contraceptives
* oestrogen therapy
* acute phase inflammatory responses
* pregnancy
· newborns
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K043571 · printed Nov 6, 2026
Cite this page
510(k) Report. “K043571: Cryocheck Clot S.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K043571
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026